Fig. 1From: Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemiaa Relapse free survival (RFS) in all 141 AML patients. b Overall survival (OS) in all 141 AML patients. c RFS in AML patients who were treated with 4 cycles and 1–2 cycles of consolidation chemotherapy (d) OS in AML patients who were treated with 4 cycles and 1–2 cycles of consolidation chemotherapyBack to article page